- Home
- IBRX vs HSAI Comparison
IBRX vs HSAI Comparison
Compare IBRX & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- HSAI
- Stock Information
- Founded
- IBRX 2014
- HSAI 2014
- Country
- IBRX United States
- HSAI China
- Employees
- IBRX N/A
- HSAI N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- HSAI
- Sector
- IBRX Health Care
- HSAI
- Exchange
- IBRX Nasdaq
- HSAI Nasdaq
- Market Cap
- IBRX 2.3B
- HSAI 2.8B
- IPO Year
- IBRX N/A
- HSAI 2023
- Fundamental
- Price
- IBRX $2.44
- HSAI $22.63
- Analyst Decision
- IBRX Strong Buy
- HSAI Strong Buy
- Analyst Count
- IBRX 5
- HSAI 2
- Target Price
- IBRX $11.40
- HSAI $27.65
- AVG Volume (30 Days)
- IBRX 7.6M
- HSAI 3.0M
- Earning Date
- IBRX 08-05-2025
- HSAI 08-18-2025
- Dividend Yield
- IBRX N/A
- HSAI N/A
- EPS Growth
- IBRX N/A
- HSAI N/A
- EPS
- IBRX N/A
- HSAI N/A
- Revenue
- IBRX $56,600,000.00
- HSAI $309,148,901.00
- Revenue This Year
- IBRX $567.98
- HSAI $61.47
- Revenue Next Year
- IBRX $160.56
- HSAI $44.10
- P/E Ratio
- IBRX N/A
- HSAI N/A
- Revenue Growth
- IBRX 4227.22
- HSAI 24.20
- 52 Week Low
- IBRX $1.83
- HSAI $3.52
- 52 Week High
- IBRX $7.48
- HSAI $24.65
- Technical
- Relative Strength Index (RSI)
- IBRX 40.38
- HSAI 58.11
- Support Level
- IBRX $2.33
- HSAI $20.66
- Resistance Level
- IBRX $2.46
- HSAI $23.20
- Average True Range (ATR)
- IBRX 0.15
- HSAI 1.19
- MACD
- IBRX -0.03
- HSAI 0.13
- Stochastic Oscillator
- IBRX 14.10
- HSAI 89.25
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About HSAI Hesai Group each ADS represents one Class B ordinary share
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.